Related Experiment Video
Updated: Jun 17, 2025
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.4K
Left Atrial Appendage Closure Compared With Oral Anticoagulants for Patients With Atrial Fibrillation: A Systematic
Angelo Oliva1,2,3, Anna Maria Ioppolo1, Mauro Chiarito2,3
1Cardiovascular Department Humanitas Gavazzeni Hospital Bergamo Italy.
Journal of the American Heart Association
|August 9, 2024
Summary
Percutaneous left atrial appendage closure (LAAC) is as effective and safe as oral anticoagulants for preventing stroke in atrial fibrillation patients. LAAC demonstrated comparable efficacy to vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) with potential bleeding benefits.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Devices
Background:
- Atrial fibrillation necessitates anticoagulation to prevent cardioembolic events.
- Percutaneous left atrial appendage closure (LAAC) is an alternative to oral anticoagulation.
- Comparative data on LAAC versus oral anticoagulants are limited.
Conclusions:
- LAAC is a non-pharmacological alternative with similar efficacy and safety to oral anticoagulation for atrial fibrillation.
- Further prospective studies are needed to confirm these findings in larger patient populations.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
657
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
657
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K